Lee S. Schwartzberg, MD, FACP

Articles

Future Directions in HR+ Breast Cancer Management

September 7th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

Clinical and Practical Implications of the Breast Cancer Index

September 7th 2022

A review of when to use the Breast Cancer Index for patients with HR+ breast cancer when deciding on endocrine therapy duration.

Biomarkers for Selection of Extended Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Experts discuss biomarkers used to determine if a patient with HR+ breast cancer will benefit from extended endocrine therapy.

Data on Extended Adjuvant Endocrine Therapy in HR+ Breast Cancer

August 26th 2022

Lee Schwartzberg, MD, FACP, explains the IDEAL study and data on the benefits of extended adjuvant endocrine therapy in HR+ breast cancer.

Ordering Additional Multigene Assays for Patients with HR+ Breast Cancer

August 19th 2022

Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.

Tools to Guide Treatment Decision-Making in HR+ Breast Cancer

August 19th 2022

Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.

Recurrence Patterns in Early-Stage HR+ Breast Cancer

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Updated Guidelines for the Management of HR+ Breast Cancer

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

The Evolution of Early-Stage HR+ Breast Cancer Management

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

Dr. Schwartzberg on Increasing Competition With Biosimilars in Oncology

November 14th 2019

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.

Dr. Schwartzberg on the Use of Therapeutic Biosimilars in Breast Cancer

November 7th 2019

Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.

Effective Management of CINV Improves Response to Treatment

January 26th 2018

The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.